Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
for Plaque Psoriasis
Drug: Deucravacitinib
122 locations incl. Birmingham
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 40+
Code: NCT07116967·Phase 3·Recruiting